|
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer
|
07 July 2016 |
|
Pfizer completes acquisition of Anacor
|
24 June 2016 |
|
Help Pfizer change the future of healthy aging
|
21 June 2016 |
|
Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer
|
06 June 2016 |
|
Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting
|
19 May 2016 |
|
Pfizer awards more than $1 million in metastatic breast cancer research funding
|
13 May 2016 |
|
Pfizer reports first-quarter 2016 results
|
03 May 2016 |
|
Pfizer announces termination of proposed combination with Allergan
|
07 April 2016 |
|
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban)
|
30 March 2016 |
|
Pfizer celebrates a year of achievements in 2015 annual review
|
16 March 2016 |
|
Pfizer commences $5 billion accelerated share repurchase
|
11 March 2016 |
|
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer
|
04 March 2016 |
|
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction
|
08 February 2016 |
|
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals
|
02 February 2016 |
|
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations
|
13 January 2016 |
|
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer
|
04 January 2016 |
|
Global partners announce donation of 500 millionth dose of azithromycin
|
17 November 2015 |
|
Pfizer expands its patient assistance program
|
10 November 2015 |
|
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline
|
06 October 2015 |
|
New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin
|
24 September 2015 |